Alizapride-13C,d3 (hydrochloride)

• UNSPSC Description:

  Alizapride-13C,d3 (hydrochloride) is deuterium labeled Alizapride (hydrochloride). Alizapride hydrochloride is a dopamine receptor antagonist with prokinetic and antiemetic effects which can also be used in the treatment of nausea and vomiting, including postoperative nausea and vomiting.

• Target Antigen:

  Dopamine Receptor; Isotope-Labeled Compounds

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  GPCR/G Protein;Neuronal Signaling;Others

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer; Neurological Disease

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(C1=CC2=C(C=C1O[13C]([2H])([2H])[2H])NN=N2)NCC3N(CCC3)CC=C.Cl

• Molecular Weight:

  355.84

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2]Bleiberg H, et al. Activity of a new antiemetic agent: alizapride. A randomized double-blind crossover controlled trial. Cancer Chemother Pharmacol. 1988;22(4):316-20.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported